巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Collegium Pharmaceutical

    COLL
    16.010
    0.140
    0.88%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Collegium Pharmaceutical - 延遲價格・最後更新於 30/09 8:28
    最高位
    16.560
    最低位
    15.940
    開市價
    --
    前收市價
    15.870
    成交量(千)
    10.39
    成交額(百萬)
    1.45
    買入
    10.040
    賣出
    22.240
    每手股數
    --
    市值(百萬)
    546.36
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    22.888 - 14.040
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Collegium Pharmaceutical
    證券代碼
    COLL.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.
    發行量
    34568709
    公司總部
    100 Technology Center Drive
    公司網址
    https://www.collegiumpharma.com
    公司電郵
    info@collegiumpharma.com
    公司電話
    +1 781 713-3699
    暫無內容

    關於

    Collegium Pharmaceutical(COLL.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.
    詳細公司背景可參考: https://www.collegiumpharma.com